Skip to main content

Table 3 Comparison of PC1/2 between patients with WT and a pfk13 NS-mutation in Asia. Metric is the fold increase of PC1/2 in mutants vs. wild type. Only mutations with n ≥ 5 are shown. With only two exceptions (K189T and K438N), all patients that carried parasites with the indicated pfk13 mutant codon showed a PC1/2 significantly different from those that carried WT parasites

From: Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatmentsa WWARN individual patient data meta-analysis

    Comparison of PC1/2
  N with N with Univariable Multivariable1
Codon mutation WT xPC1/2 95%CI p value xPC1/2 95% CI p value
K189T 8 148 1.1 0.8–1.4 0.729 1.1 0.8–1.4 0.644
E252Q 114 589 1.5 1.4–1.6 < 0.001 1.5 1.4–1.6 < 0.001
K438N 10 386 0.9 0.7–1.1 0.251 0.9 0.7–1.1 0.237
P441L 53 565 2.1 1.9–2.3 < 0.001 2.2 2.0–2.4 < 0.001
F446I 79 303 1.6 1.4–1.7 < 0.001 1.5 1.4–1.7 < 0.001
G449A 6 41 1.9 1.4–2.6 < 0.001 1.9 1.3–2.7 < 0.001
N458Y 34 520 2.5 2.2–2.8 < 0.001 2.5 2.2–2.8 < 0.001
M476I 8 481 2 1.6–2.5 < 0.001 2.0 1.5–2.5 < 0.001
A481V 5 410 1.8 1.3–2.4 < 0.001 1.6 1.2–2.2 0.002
Y493H 33 313 2.6 2.2–3.0 < 0.001 2.7 2.3–3.1 < 0.001
R515K 5 352 1.9 1.4–2.6 < 0.001 2.0 1.5–2.7 < 0.001
P527H/L* 23 422 1.7 1.5-2.0 < 0.001 1.7 1.5–2.0 < 0.001
N537I 8 231 1.7 1.3–2.2 < 0.001 1.8 1.4–2.3 < 0.001
G538V 24 558 1.8 1.6–2.1 < 0.001 1.9 1.6–2.2 < 0.001
R539T 76 369 2.1 1.9–2.4 < 0.001 2.1 1.9–2.4 < 0.001
I543T 92 156 1.9 1.7–2.3 < 0.001 2.1 1.8–2.4 < 0.001
I543T** 27 140 2.8 2.3–3.4 < 0.001 2.8 2.3–3.5 < 0.001
P553L 16 529 2.2 1.8–2.6 < 0.001 2.2 1.8–2.8 < 0.001
R561H 36 310 2.2 1.9–2.5 < 0.001 2.2 1.9–2.6 < 0.001
V568G 5 127 2.7 1.8–4.1 < 0.001 2.7 1.8–4.1 < 0.001
P574L 48 739 1.8 1.6–2.0 < 0.001 2.0 1.7–2.2 < 0.001
P574L*** 35 723 1.8 1.6–2.1 < 0.001 1.8 1.6–2.1 < 0.001
C580Y 450 997 2.2 2.1–2.4 < 0.001 2.3 2.1–2.4 < 0.001
P667T**** 5 50 2.2 1.6–2.9 < 0.001 2.1 1.6–2.9 < 0.001
A675V 49 501 2.2 1.9–2.4 < 0.001 2.2 2.0–2.4 < 0.001
  1. 1Adjusted for total artemisinin derivative dose in the first 3 days, partner drug, initial parasitemia and patient age
  2. *20 P527H, one P527L, analyzed together, two P527H not analyzed since clearance data did not meet criteria
  3. **With study ID 8, study site ID 23 (Tra Lang) removed
  4. ***With study ID 13, study site ID 15 (Pyin Oo Lwin) removed
  5. ****5 P667T, one P667T not analyzed since clearance data did not meet criteria